More than 75% of cancer-related deaths occur from cancers for which we do not screen. OncoVeryx may help fill these clinical gaps.
OncoVeryx aims to provide early and precise detection of cancers in asymptomatic and high risk women and men. The test utilizes advanced LC/MS-MS technologies to screen for 32 cancers from a single blood draw.
Notably, in positive cases, the test can identify the tissue of origin among 17 different types.
Through extensive research and technological advancements, we are dedicated to developing a highly accurate and reliable test that can significantly improve early intervention and treatment outcomes.
Join us in the future of cancer diagnostics with our innovative 32 Cancer OncoVeryx Test.
Liver + Bile
Sq. cell carcinoma
Brain & CNS
Germ cell tumor